Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

NY-ESO-1 is a “cancer-testis” antigen expressed in many cancers. ISCOMATRIX is a saponin-based adjuvant that induces antibody and T cell responses. We performed a placebo-controlled clinical trial evaluating the safety and immunogenicity of recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant. Fort...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Davis, Ian D., Chen, Weisan, Jackson, Heather, Parente, Phillip, Shackleton, Mark, Hopkins, Wendie, Chen, Qiyuan, Dimopoulos, Nektaria, Luke, Tina, Murphy, Roger, Scott, Andrew M., Maraskovsky, Eugene, McArthur, Grant, MacGregor, Duncan, Sturrock, Sue, Tai, Tsin Yee, Green, Simon, Cuthbertson, Andrew, Maher, Darryl, Miloradovic, Lena, Mitchell, Susan V., Ritter, Gerd, Jungbluth, Achim A., Chen, Yao-Tseng, Gnjatic, Sacha, Hoffman, Eric W., Old, Lloyd J., Cebon, Jonathan S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: National Academy of Sciences 2004
Schlagworte:
Biological Sciences
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC489997/
https://ncbi.nlm.nih.gov/pubmed/15252201
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0403572101
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge